# US 2020/0262885 A1 · Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0262885 A1
- Document ID: US20200262885A1
- Status: Published application
- Kind: A1
- Application number: 16/061,421
- Filed: 2016-12-12
- Published: 2020-08-20
- Earliest claimed: 2015-12-14
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Torsten HAACK; Oliver PLETTENBURG; Andreas EVERS; Michael WAGNER; Martin BOSSART; Romain BETRAND
- Web page: https://patentgrep.com/patent/US20200262885A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/28: Insulins
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.

## Claims

### Claim 1

A peptidic compound having the formula (I):
(I)
Tza-X2-X3-Gly-Thr-Phe-X7-Ser-Asp-X10-Ser-X12-X13-
X14-X15-X16-X17-X18-Ala-X20-X21-Phe-Ile-Glu-Trp-
Leu-Leu-X28-X29-Gly-Pro-X32-Ser-Gly-Ala-Pro-Pro-
Pro-Ser-X40-R1
X2 represents an amino acid selected from Ser and d-Ser,
X3 represents an amino acid selected from Gln and His,
X7 represents an amino acid selected from Thr and Aib,
X10 represents an amino acid residue selected from Tyr, Leu, Val, Ile, Phe, Phenylglycine, Thr, 2-Fluorophenylalanine, Cyclohexylglycine and tert-Leucine
X12 represents an amino acid selected from Lys, Arg and Cys(VS-DO3A),
X13 represents an amino acid selected from Gln, Tyr and Cys(VS-DO3A),
X14 represents an amino acid residue selected from Leu, Nle and Cys(VS-DO3A),
X15 represents an amino acid selected from Glu and Asp,
X16 represents an amino acid selected from Ser, Glu, Aib and Cys(VS-DO3A),
X17 represents an amino acid selected from Arg, Gln, Lys, Ala and Cys(VS-DO3A),
X18 represents an amino acid selected from Arg, Lys and Ala,
X20 represents an amino acid selected from Gln, Glu, Aib, Lys and Cys(VS-DO3A),
If X16 is Glu and X20 is Lys, the sidechains of X16 and X20 may form a cyclic ring via a lactam,
X21 represents an amino acid residue selected from Asp and Glu,
X28 represents an amino acid selected from Ala and β-Ala,
X29 represents an amino acid residue selected from Gly and Thr,
X32 represents an amino acid selected from Glu and Ser,
X40 represents an amino acid selected from Cys(VS-DO3A), Cys(VS-NO2A), Cys(mal-DOTA), Cys(mal-NOTA), Cys(mal-NODAGA), Lys(DOTA), Lys(NOTA), Lys(PEG-DOTA) and Lys(VS-DO3A),
X40 may be absent if one of the amino acids X12, X13, X14, X16, X17 or X20 is Cys(VS-DO3A),
wherein DOTA, NOTA, DO3A, NO2A or NODAGA may be unloaded or loaded with a metal ion selected from Gd3+, Ga3+, Cu2+, (Al—F)2+, Y3+, Tc3+, In3+, Lu3+ and Re3+,
R1 represents OH or NH2;
or a metal complex or a salt or a solvate thereof.

### Claim 2 (depends on 1)

A compound of formula (I) according to claim 1, wherein
X2 represents an amino acid selected from Ser and d-Ser,
X3 is Gln,
X7 represents an amino acid selected from Thr and Aib,
X10 represents an amino acid residue selected from Tyr, Leu, Ile,
X12 is Lys,
X13 is Gln,
X14 represents an amino acid residue selected from Leu and Nle,
X15 represents an amino acid selected from Glu and Asp,
X16 represents an amino acid selected from Ser and Glu,
X17 represents an amino acid selected from Arg and Gln,
X18 is Arg,
X20 represents an amino acid selected from Gln and Lys,
If X16 is Glu and X20 is Lys, the sidechains of X16 and X20 may form a cyclic ring via a lactam,
X21 represents an amino acid residue selected from Asp and Glu,
X28 is Ala,
X29 represents an amino acid residue selected from Gly and Thr,
X32 is Glu,
X40 is Cys(VS-DO3A),
wherein DO3A, may be unloaded or loaded with a metal ion selected from Gd3+, Ga3+, Cu2+, (Al—F)2+, Y3+, Tc3+, In3+, Lu3+ and Re3+,
R1 represents OH or NH2;
or a metal complex or a salt or a solvate thereof.

### Claim 3 (depends on 1)

A compound of formula (I) according to claim 1, selected from the compounds of SEQ ID NO: 3-90 as well as a metal complex, salts or solvates thereof.

### Claim 4 (depends on 1)

A compound of formula (I) according to claim 1, selected from the compounds of SEQ ID NO: 6, 8, 13, 14, 35, 36, 49, 50, 60, 61, 79, 80, 85 and 86 as well as a metal complex, salts or solvates thereof.

### Claim 5 (depends on 1)

A compound of formula (I) according to claim 1, wherein
DOTA, NOTA, DO3A, NO2A or NODAGA is loaded with a metal ion Ga3+.

### Claim 6 (depends on 1)

A compound of formula (I) according to claim 1, wherein
DOTA, NOTA, DO3A, NO2A or NODAGA is loaded with a metal ion Gd3+.

### Claim 7 (depends on 1)

A compound of formula (I) according to claim 1, wherein
DOTA, NOTA, DO3A, NO2A or NODAGA is loaded with a metal radionucleotide ion (Cu-64)2+, (Ga-68)3+, (Al—F-18)2+, (Y-86)3+.

### Claim 8 (depends on 1)

A compound of formula (I) according to claim 1, wherein DOTA, NOTA, DO3A, NO2A or NODAGA is loaded with a metal radionucleotide ion (Ga-67)3+, (Tc-99m)3+, (In-111)3+.

### Claim 9 (depends on 1)

A compound of formula (I) according to claim 1, wherein DOTA, NOTA, DO3A, NO2A or NODAGA is loaded with a metal radionucleotide ion selected from (Cu-67)2+, (Y-90)3+, (In-111)3+, (Lu-177)3+, (Re-186)3+ and (Re-188)3+.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising at least one compound according to claim 1 or a physiologically acceptable salt or solvents of any of them.

### Claim 11 (depends on 10)

The compound for use according to claim 10 which is present as an active agent in a pharmaceutical composition together with at least one pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A compound according to claim 1 for visualization of the glucagon receptor in living subjects and relevant tissues.

### Claim 13 (depends on 1)

A compound of claim 1 for use in medicine, particularly in human medicine.

### Claim 14 (depends on 6)

A compound according to claim 6 for visualization of the glucagon receptor in living subjects and relevant tissues by MRI.

### Claim 15 (depends on 7)

A compound according to claim 7 for visualization of the glucagon receptor in living subjects and relevant tissues by PET.

### Claim 16 (depends on 8)

A compound according to claim 8 for visualization of the glucagon receptor in living subjects and relevant tissues by SPECT.

### Claim 17 (depends on 9)

A compound according to claim 9 for use in radiotherapy.

### Claim 18 (depends on 1)

The compound for use according to claim 1 for treating hypoglycemia, increase blood glucose levels, or as adjunctive therapy with insulin.

### Claim 19 (depends on 1)

A method for treating hypoglycemia in a patient, the method comprising administering to the patient an effective amount of at least one compound of formula (I) according to claim 1.

### Claim 20 (depends on 19)

The method according to claim 19 which is administered parenterally.
